Koo,

You wrote: "Is this in comparison to the 30% Don is aiming for with the BoM? Is this apple to apple comparison?"

I don't know what you mean by "this". One of the several results disclosed in yesterday's EASD presentation on EMPA-REG OUTCOME with Jardiance was that they had achieved a 14% relative risk reduction (RRR), or 0.86 hazard ratio, for the number of patients experiencing an event in the 3-point MACE category (death, non-fatal heart attack, non-fatal stroke). However, they also reported RRR for the individual events of death, non-fatal heart attack, non-fatal stroke, hospitalizations, death by all causes, etc. So "this" is a vague term. The apple to apple comparison is that EMPA-REG OUTCOME acheived a 14% RRR (p=0.0382) for the 3-point MACE when comparing the ~4600 treated patients with the ~2300 control patients; whereas Resverlogix (according to Don at last Fridays Rodman and Renshaw) is aiming for 30% RRR for the same 3-point MACE metric in the upcoming BETonMACE trial with RVX-208/apabetalone.

Hopefully that clears it up for you.

BearDownAZ